LMH STRATEGIC SOLUTIONS for INCYTE CORPORATION
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 2nd Quarter - Report (this page) | Jul 5, 2026 | $50,000 | Replaced |
| 2nd Quarter - Termination | Oct 19, 2026 | $50,000 | Yes |
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Healthcare-related legislative and regulatory issues impacting the biotechnology, pharmaceutical, and consumer health industry.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ALANNA TEMME | — |
Pharmacy PHA
Healthcare-related legislative and regulatory issues impacting the biotechnology, pharmaceutical, and consumer health industry.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ALANNA TEMME | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.